SI3294740T1 - Nove sulfonimidoilpurinonske spojine in derivati za zdravljenje virusne okužbe in zaščito pred njo - Google Patents

Nove sulfonimidoilpurinonske spojine in derivati za zdravljenje virusne okužbe in zaščito pred njo

Info

Publication number
SI3294740T1
SI3294740T1 SI201630473T SI201630473T SI3294740T1 SI 3294740 T1 SI3294740 T1 SI 3294740T1 SI 201630473 T SI201630473 T SI 201630473T SI 201630473 T SI201630473 T SI 201630473T SI 3294740 T1 SI3294740 T1 SI 3294740T1
Authority
SI
Slovenia
Prior art keywords
prophylaxis
derivatives
novel
treatment
virus infection
Prior art date
Application number
SI201630473T
Other languages
English (en)
Slovenian (sl)
Inventor
Chungen Liang
Kun Miao
Jianping Wang
Hongying Yun
Xiufang Zheng
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55910966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3294740(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of SI3294740T1 publication Critical patent/SI3294740T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI201630473T 2015-05-08 2016-05-04 Nove sulfonimidoilpurinonske spojine in derivati za zdravljenje virusne okužbe in zaščito pred njo SI3294740T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2015078507 2015-05-08
CN2016078785 2016-04-08
PCT/EP2016/059961 WO2016180695A1 (en) 2015-05-08 2016-05-04 Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
EP16720421.3A EP3294740B1 (en) 2015-05-08 2016-05-04 Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection

Publications (1)

Publication Number Publication Date
SI3294740T1 true SI3294740T1 (sl) 2019-12-31

Family

ID=55910966

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201630473T SI3294740T1 (sl) 2015-05-08 2016-05-04 Nove sulfonimidoilpurinonske spojine in derivati za zdravljenje virusne okužbe in zaščito pred njo

Country Status (32)

Country Link
US (3) US9708325B2 (enExample)
EP (1) EP3294740B1 (enExample)
JP (1) JP6738352B2 (enExample)
KR (1) KR102690131B1 (enExample)
CN (1) CN107580596B (enExample)
AR (1) AR104528A1 (enExample)
AU (3) AU2016260683B2 (enExample)
BR (1) BR112017023959B1 (enExample)
CA (1) CA2982704C (enExample)
CL (1) CL2017002745A1 (enExample)
CO (1) CO2017009994A2 (enExample)
CR (1) CR20170496A (enExample)
DK (1) DK3294740T3 (enExample)
ES (1) ES2753777T3 (enExample)
HR (1) HRP20191942T1 (enExample)
HU (1) HUE045906T2 (enExample)
IL (2) IL254947B (enExample)
LT (1) LT3294740T (enExample)
MX (2) MX376761B (enExample)
MY (1) MY182353A (enExample)
NZ (2) NZ735648A (enExample)
PE (1) PE20171620A1 (enExample)
PH (1) PH12017502009A1 (enExample)
PL (1) PL3294740T3 (enExample)
PT (1) PT3294740T (enExample)
RS (1) RS59435B1 (enExample)
RU (1) RU2745269C2 (enExample)
SG (1) SG10202108841YA (enExample)
SI (1) SI3294740T1 (enExample)
TW (2) TWI768467B (enExample)
UA (1) UA120450C2 (enExample)
WO (1) WO2016180695A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ735648A (en) 2015-05-08 2023-06-30 Hoffmann La Roche Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
SG11201901633WA (en) 2016-08-29 2019-03-28 Hoffmann La Roche 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
WO2018050571A1 (en) * 2016-09-13 2018-03-22 F. Hoffmann-La Roche Ag Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
EP3752505B1 (en) 2018-02-12 2023-01-11 F. Hoffmann-La Roche AG Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection
CA3091950A1 (en) * 2018-02-28 2019-09-06 F. Hoffmann-La Roche Ag 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
CN111072667A (zh) * 2018-10-22 2020-04-28 罗欣药业(上海)有限公司 五元或六元杂环并嘧啶类化合物及其用途
CN119455003A (zh) * 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
CN114450280B (zh) 2019-09-20 2025-02-25 先正达农作物保护股份公司 具有含硫和亚砜亚胺取代基的杀有害生物活性杂环衍生物
US20230131192A1 (en) * 2020-01-27 2023-04-27 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
KR20220132590A (ko) * 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
WO2024013205A1 (en) 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag Phosphorylpurinone compounds for the treatment of cancer
CN118724963A (zh) * 2023-03-30 2024-10-01 浙江养生堂天然药物研究所有限公司 含磷或含硫的大环化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
JP2008540396A (ja) * 2005-05-04 2008-11-20 ファイザー・リミテッド 癌およびc型肝炎などのウイルス感染を治療するためのトール様受容体調節薬としての2−アミド−6−アミノ−8−オキソプリン誘導体
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
PE20120106A1 (es) 2008-12-09 2012-02-20 Gilead Sciences Inc Moduladores de receptores tipo toll
WO2011079016A1 (en) 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
JP6349256B2 (ja) 2011-11-09 2018-06-27 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染の治療のためのプリン誘導体
PL2978429T3 (pl) 2013-03-29 2017-08-31 Janssen Sciences Ireland Uc Deazapurynony makrocykliczne do leczenia infekcji wirusowych
BR112017002811B1 (pt) 2014-08-15 2022-09-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Compostos de pirrolopirimidina usados como agonista de tlr7 e seu uso, composição farmacêutica e kit
NZ735648A (en) * 2015-05-08 2023-06-30 Hoffmann La Roche Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
SG11201901633WA (en) * 2016-08-29 2019-03-28 Hoffmann La Roche 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection

Also Published As

Publication number Publication date
US9708325B2 (en) 2017-07-18
TW201716410A (zh) 2017-05-16
BR112017023959A2 (pt) 2018-07-17
AU2016260683A1 (en) 2017-10-12
PE20171620A1 (es) 2017-11-02
RU2745269C2 (ru) 2021-03-22
TW202108584A (zh) 2021-03-01
SG10202108841YA (en) 2021-09-29
PT3294740T (pt) 2019-10-29
HUE045906T2 (hu) 2020-01-28
ES2753777T3 (es) 2020-04-14
AR104528A1 (es) 2017-07-26
RS59435B1 (sr) 2019-11-29
MY182353A (en) 2021-01-20
BR112017023959B1 (pt) 2023-05-02
NZ735648A (en) 2023-06-30
MX393198B (es) 2025-03-19
TWI706954B (zh) 2020-10-11
CN107580596B (zh) 2020-07-14
MX2020010949A (es) 2022-06-16
IL280769B1 (en) 2023-03-01
US20170275286A1 (en) 2017-09-28
EP3294740B1 (en) 2019-09-04
IL280769A (en) 2021-04-29
CL2017002745A1 (es) 2018-05-18
CO2017009994A2 (es) 2018-02-20
HK1247925A1 (zh) 2018-10-05
AU2022204666A1 (en) 2022-07-21
LT3294740T (lt) 2019-11-25
US20160326177A1 (en) 2016-11-10
PH12017502009A1 (en) 2018-03-26
CR20170496A (es) 2017-12-05
NZ775222A (en) 2024-09-27
US10399983B2 (en) 2019-09-03
RU2017142577A (ru) 2019-06-10
AU2020256348B2 (en) 2022-06-16
CA2982704A1 (en) 2016-11-17
CN107580596A (zh) 2018-01-12
IL254947A0 (en) 2017-12-31
AU2020256348A1 (en) 2020-11-12
JP2018515509A (ja) 2018-06-14
DK3294740T3 (da) 2019-11-04
WO2016180695A1 (en) 2016-11-17
HRP20191942T1 (hr) 2020-01-10
UA120450C2 (uk) 2019-12-10
EP3294740A1 (en) 2018-03-21
CA2982704C (en) 2023-10-24
KR20180003612A (ko) 2018-01-09
US11242345B2 (en) 2022-02-08
US20200109144A1 (en) 2020-04-09
IL280769B2 (en) 2023-07-01
PL3294740T3 (pl) 2020-03-31
MX2017014033A (es) 2018-03-01
MX376761B (es) 2025-03-07
IL254947B (en) 2021-02-28
AU2016260683B2 (en) 2020-10-29
KR102690131B1 (ko) 2024-07-31
TWI768467B (zh) 2022-06-21
JP6738352B2 (ja) 2020-08-12
RU2017142577A3 (enExample) 2019-10-31

Similar Documents

Publication Publication Date Title
IL280769B1 (en) Novel sulfonimidylpurinone compounds and their history for the treatment and prevention of virus infection
IL284255A (en) 7-substituted sulfonimidylpurinone compounds for the treatment and prevention of viral infection
IL245436A0 (en) New dihydroquinolizinones for the treatment and prevention of hepatitis b virus infection
IL246449A0 (en) 6-compressed new heteroaryldihydropyrimidines for the treatment and prevention of hepatitis b virus infection
IL263972A (en) Dihydropyranopyrimidines for the treatment of viral infections
SG11201509463YA (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
ZA201705634B (en) Quinoline derivatives for use in the treatment or prevention of viral infection
EP3280422A4 (en) Compositions and methods for the treatment of hbv infection
SG11201702766YA (en) Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (rsv)
PL3137078T3 (pl) Leczenie zakażenia wirusem zapalenia wątroby typu delta
ZA201900770B (en) 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
LT3504210T (lt) Nauji 7 padėtyje pakeisti sulfonimidoilpurinono junginiai, skirti viruso sukeliamos infekcijos gydymui ir profilaktikai
ZA201604784B (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection